• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

药物偶联物连接子的最新进展

Recent Advances in the Linkers of Drug Conjugates.

作者信息

Deng Shirui, Wen Xiaoan, Wang Jinzheng

机构信息

School of China Pharmaceutical University, Nanjing, China.

Department of Lingang Laboratory, Shanghai, China.

出版信息

Curr Med Chem. 2024 Sep 16. doi: 10.2174/0109298673320170240829110110.

DOI:10.2174/0109298673320170240829110110
PMID:39289930
Abstract

Drug conjugates have emerged as a pivotal research focus in the field of targeted cancer therapy. They represent a widely explored prodrug strategy that significantly enhances the therapeutic index of drugs while minimizing side effects. The stability and selective cleavage of the linker within drug conjugates are critical for the therapeutic efficacy and targeted treatment achieved by these conjugates. In this review, we have categorized the linkers based on their cleavage mode and summarized the chemical properties, advantages, and limitations of various types of cleavable linkers. Particularly, examples have been provided to illustrate their specific potential for development.

摘要

药物偶联物已成为靶向癌症治疗领域的一个关键研究重点。它们代表了一种广泛探索的前药策略,能显著提高药物的治疗指数,同时将副作用降至最低。药物偶联物中连接子的稳定性和选择性裂解对于这些偶联物实现的治疗效果和靶向治疗至关重要。在本综述中,我们根据连接子的裂解模式对其进行了分类,并总结了各类可裂解连接子的化学性质、优点和局限性。特别提供了实例来说明它们的具体开发潜力。

相似文献

1
Recent Advances in the Linkers of Drug Conjugates.药物偶联物连接子的最新进展
Curr Med Chem. 2024 Sep 16. doi: 10.2174/0109298673320170240829110110.
2
Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.串联切割连接子提高抗体药物偶联物的体内稳定性和耐受性。
Bioconjug Chem. 2021 Apr 21;32(4):746-754. doi: 10.1021/acs.bioconjchem.1c00029. Epub 2021 Mar 9.
3
Sulfatase-cleavable linkers for antibody-drug conjugates.用于抗体药物偶联物的硫酸酯酶可裂解连接子。
Chem Sci. 2020 Jan 27;11(9):2375-2380. doi: 10.1039/c9sc06410a.
4
Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.抗体药物偶联物中的溶酶体可裂解肽接头
Biomedicines. 2023 Nov 16;11(11):3080. doi: 10.3390/biomedicines11113080.
5
Research advances in peptide‒drug conjugates.肽-药物偶联物的研究进展
Acta Pharm Sin B. 2023 Sep;13(9):3659-3677. doi: 10.1016/j.apsb.2023.02.013. Epub 2023 Feb 28.
6
ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development.药物研发中不可裂解连接子的吸收、分布、代谢、排泄及安全性方面
Curr Top Med Chem. 2017;17(32):3463-3475. doi: 10.2174/1568026618666180118153502.
7
Cleavable linkers in antibody-drug conjugates.抗体药物偶联物中的可裂解连接子。
Chem Soc Rev. 2019 Aug 12;48(16):4361-4374. doi: 10.1039/c8cs00676h.
8
Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.光可移除连接子的开发作为改善药物偶联物药代动力学的新策略及其在癌症治疗抗体药物偶联物中的潜在应用
Pharmaceuticals (Basel). 2022 May 25;15(6):655. doi: 10.3390/ph15060655.
9
Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.通过组织蛋白酶B敏感二肽接头的自动固相掺入工程化酶可切割的寡核苷酸。
Angew Chem Weinheim Bergstr Ger. 2022 Mar 21;134(13):e202114016. doi: 10.1002/ange.202114016. Epub 2022 Feb 10.
10
Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.通过从大分子缀合物中控制化学释放来延长治疗剂的半寿期,使其具有可预测性和可调性。
Proc Natl Acad Sci U S A. 2012 Apr 17;109(16):6211-6. doi: 10.1073/pnas.1117147109. Epub 2012 Apr 2.

引用本文的文献

1
Recent Advances in Smart Linkage Strategies for Developing Drug Conjugates for Targeted Delivery.用于开发靶向递送药物偶联物的智能连接策略的最新进展
Top Curr Chem (Cham). 2025 Mar 13;383(2):13. doi: 10.1007/s41061-025-00497-w.
2
Current Trends in Clinical Trials of Prodrugs.前体药物临床试验的当前趋势。
Pharmaceuticals (Basel). 2025 Feb 4;18(2):210. doi: 10.3390/ph18020210.